Lindsay Rosenwald’s History & Accomplishments

0 comments

Posted on 15th September 2011 by emorgan in Lindsay Rosenwald Info

,

Biotechnology is an industry that is really taking off these days, and Dr. Lindsay Rosenwald is at the helm of its development. Dr. Rosenwald’s investment portfolio is diverse. He invests in companies devoted to various endeavors, from research to developments in drugs.

Dr. Lindsay Rosenwald has made a name for himself on Wall Street where he is a well-respected venture capitalist and hedge fund manager. He also has a long-lasting reputation in various fields of medicine and life-sciences research. In the arenas of healthcare and biotechnology, he is a leader, always at the forefront of R&D innovations. His singular experience combining the reaches of science with the power of finance has given Dr. Rosenwald the keen ability to create new avenues of research as well as find promising companies to invest in. His contributions are as countless as they are impacting. Millions of people across the world have benefited from healthcare that is, today, more far-reaching, a reality that Dr. Rosenwald has helped to create. There is hardly another person who can compare with the level of achievements Dr. Rosenwald has collectively made in these various fields.

In the progress of his brilliant career, spanning almost two decades, Dr. Lindsay A. Rosenwald, has established and re-capitalized many public and private life-science and biotech companies.

After finishing up high school at Abington in 1973, Rosenwald began his college career at Pennsylvania State University. He graduated with a degree in Finance. He continued his education at the Temple University School of Medicine and completed his internship at Abington Medical Hospital. Thereafter, Rosenwald sustained his own private practice in medicine before moving on to other horizons. On Wall Street, he combined his two expert subjects, finance and medicine, and carving his way, he continued to walk the path to success.

Between 1994 and 2007, Rosenwald played the role of executive director for the Aries Funds. The Funds invested over $1 billion into healthcare. From 2002 to 2006, Rosenwald took another executive position, at the head of the Orion Fund which specifically invested in biotechnology initiatives, especially private investments in public equity.

Dr. Rosenwald established a non-profit organization called the Rosenwald Foundation. The organization is devoted to supporting many scientific, healthcare and educational companies.

Rosenwald’s approach to medicine in conjunction with finance has encouraged him on his unique path. His approach allows him to pursue new angles in medicine, biotechnology and life sciences.

Dr. Rosenwald is currently a director at the Republican Jewish Coalition and also serves as president of Paramount Group. The Paramount Group’s specialty is in investment banking, R&D, and equity management in life-sciences and biotechnology. One of Dr. Rosenwald’s most recent undertakings is the OpusPoint Partners, LLC which was created in 2009. The new company’s aim is to offer support to promising endeavors and new accomplishments in life-sciences and biotechnology. OpusPoint Partners is committed to ground-breaking innovations and technologies in these industries.

Notable achievements by Dr. Lindsay Rosenwald and his team include providing funding for numerous companies and drug candidates that show promise. Cougar Biotechnology Inc., in L.A., is one of these companies. Its primary mandate is fighting cancer and has recently produced a new drug for aggressive forms of prostate cancer called Abiraterone. In 2009, Johnson & Johnson gained possession of this auspicious company for $1 billion after negotiating with Dr. Rosenwald.

Dr. Rosenwald and OpusPoint Partners will continue to seek opportunities for projects like this one. With these kinds of initiatives, they hope to change the face of medicine and life sciences, at the same time changing the rest of the world.

By establishing solid relationships and building upon their successes, OpusPoint Partners, along with Dr. Rosenwald’s leadership, will meet their goals. They already have an entire host of avant-garde credits to their name. Dr. Rosenwald is a truly innovative leader. He was the first investor in the first obesity drug in the US market. He was also the first founder of a stem cell company that trades publicly. The development of the first public gene therapy company owes its development to Dr. Rosenwald. Other accomplishments that Rosenwald has been involved in include the first cancer vaccine made available to the public.

Currently, Dr. Lindsay Rosenwald and OpusPoint Partners seek to create strong relationships with other leaders that share the same values and attitude to business and who are also passionate about finding and supporting breakthrough technologies.

With this level of determination, skill and methodology, OpusPoint Partners and its two founders, Dr. Rosenwald and Michael S. Weiss, have a broad and stable future ahead of them. The investments that they collectively make are bound to leave a very lasting impression on the way we look at disease.

OpusPoint Partners: Trailblazers of the Healthcare and Life Sciences Revolution

0 comments

Posted on 12th September 2011 by emorgan in Lindsayrosenwald

,

When OpusPoint Partners was started in 2009 by Michael S. Weiss and Dr. Lindsay Rosenwald it was then just one of a number of biotechnology companies founded by these two men who have jointly had more than 40 years combined experience and expertise in the area of investing in biotechnological research.

Today, OpusPoint Partners has retained its position at the forefront of the life science and healthcare industries, revolutionizing the way that money is allocated towards investments for the advancement of healthcare and life sciences with a view to improving the quality of life for people from all over the world. The company is confident that under the dual leadership of these two gentlemen, the healthcare industry will improve how diseases are diagnosed and how healthcare treatment is delivered to patients to continue to meet the needs of the patients more effectively.

OpusPoint Partners under the guidance of Dr. Lindsay Rosenwald has stood steadfast in its commitment to practice integrity and still attain all of its short and long term goals. They seek to form a team which includes both the investors and the researchers working together in a quest to advance the future of medical care. Working relationships such as these which bring together the investment with the biotechnology build on a foundation of trust that brings out a high measure of honesty in the investing and full disclosure in all the related company’s dealings. This is where the team put together by OpusPoint Partners is then able to discover emerging companies and invest funds and resources into these enterprises where promising results are already being seen in the fields of healthcare and life sciences.

There is fierce competition in this industry and as a result OpusPoint Partners has established a solid conglomeration of organizations that know that it is easy to get lost by employing tactics that are not very ethical, in order to beat the system and to improve their earnings when performing clinical trials. This conglomeration maintains its guiding principles which sticks to its integrity and forfeits the dangerous short cuts. This is the essence that makes OpusPoint partners unique, being fair and loyal to its employees and its investors and not compromising when it comes to the research and the development of drugs through all of the trial stages and the final manufacturing stages.

These policies ensure that OpusPoint Partners will continue to be trailblazers, providing invaluable assistance for public companies and for businesses that are now starting up. This assistance comes in the form of advisory services and investments, believing that the mission to improve innovative companies bring a corresponding increase in the volume of medical breakthroughs which occur and having a ripple effect of improving the lives of many people.

The commitment and dedication to improving the way in which biotech investing is done is maintained by imposing strong moral values and by using strong business practices. Investors are then afforded excellent returns with minimal risk, a straight forward formula that proves the worthiness of this methodology. The success of this commitment has not gone without its rewards. Dr. Rosenwald highlighted that in the past few years, the company far exceeded its performance projections and was instrumental in significantly improving the financial health of more than twenty companies, earning them excellent accolades in the areas of drug research and finance and also earning excellent risk adjusted returns for its investors.

The mission of transforming present day healthcare and medical techniques and procedures as expected is not an easy undertaking. Time and commitment backed with hard work will support the provision of funding and bring promising results without compromising the ethical standards of the industry or losing earnings.

Dr. Lindsay Rosenwald is a member of the Board of Directors of the Republican Jewish Coalition and has formed many allegiances with many key individuals in the biotechnology financial sector. His illustrious career includes more than seventeen years as a Wall Street biotechnology investor. Dr. Rosenwald also founded the company Cougar Biotechnology Inc. in Los Angeles which is focused on the production of experimental drugs that treat cancer. One of these drugs has had remarkable success because of its effectiveness in the treatment of late stage prostate cancer. Johnson & Johnson acquired Cougar Biotech Labs on July 10th 2009 at a cost of over one billion dollars.

Dr. Lindsay Rosenwald managed the Aries Funds from 1994 to 2007 and this fund in the Year 2000, administered over $1B in healthcare investments. He also managed the Orion Fund from 2002 to 2006 which is a committed capital fund which is dedicated to private investments in biotechnology which also includes the PIPEs. With this wealth of experience come a medical degree from the Temple University School of Medicine and a finance degree from the Pennsylvania State University.

Dr. Rosenwald has established and re-capitalized quite a number of private and public sector biotechnology and life sciences companies. OpusPoint Partners anticipates that under his joint leadership, its successes will continue to set the trails ablaze well into the future.

OpusPoint Partners: Making New Discoveries in Biotechnology

0 comments

Posted on 9th September 2011 by emorgan in Lindsayrosenwald

,

OpusPoint Partners was co-founded in 2009 by Lindsay Rosenwald, M.D., and Michael Weiss. This revolutionary joint venture was to be one that assisted in putting a necessary focus on the growth of emerging biotechnology and life science companies. The promising studies and trials performed by these up and coming biotech firms are what potentially can stamp out life threatening illnesses around the world.

Rosenwald and Weiss recognized the need to support the efforts of these developing companies and through OpusPoint Partners they are able to make the ideal notion of a world with less disease a possibility.

Both men have an overwhelming passion for creating and buttressing biotechnology and life science studies, and each has done so for over 20 years respectively. Lindsey Rosenwald and Michael Weiss have both independently and jointly invested in the development of biotech companies, helping them grow with their expertise and finely tuned ethic compass. It is their desires to not only see these life science and biotech firms succeed but to do so justly without deception.

Lindsay Rosenwald brings his extraordinary knowledge of both finance and biotechnology into play with OpusPoint Partners. Dr. Rosenwald has accomplished much in both his academic life and professional career. He holds two degrees, a Bachelor of Science in Finance from Pennsylvania State University and a Doctor of Medicine from Temple University School of Medicine.

Beyond Rosenwald’s academic achievements, he is a successful entrepreneur in the biotechnology field. He has been the driving force behind nearly 50 biotech companies over the span of 20+ years. One of these successful ventures was Cougar Biotechnology Inc., which among its many intriguing studies and drug trials a notable drug that helped thwart the growth prostate cancer in the late stages was discovered. In 2009 Lindsay Rosenwald sold Cougar Biotechnology to Johnson & Johnson for roughly one billion dollars. It is around this time that Rosenwald and Weiss teamed up for a new endeavor together.

With Dr. Rosenwald’s track record it is safe to say that that he has a knack for creating biotech success. Over the last few years with OpusPoint Partners he has aided approximately 20 biotech companies expand their businesses and studies to an extent that would have not been fathomable without the positive backing from the co-founders of this remarkable biotechnology investing firm.

OpusPoint Partners through the assistance of Lindsay Rosenwald as well as other biotech and life science investors are trying to bring a change to the field of drug development by giving biotech companies a fighting chance to make a positive impact in the world of medicine. This desire to influence innovation is based on strong ethical standards and a shared belief that integrity and advance technological thinking is what makes a good biotech business thrive.

This biotechnology investing company doesn’t solely work on their own, OpusPiont Partners also works alongside other investors, researchers, and corporations to find and contribute to the development of biotechnology firms that have great aspirations and ideas but lack the financials and bureaucratic know how to achieve their scientific goals. Lindsay Rosenwald is there to act as a guiding force pathing the way for emergent biotech companies to make a splash in the discovery of life saving drugs.

Dr. Rosenwald has proven time and time again that he is more than adept at making and administrating appropriate investments that are beneficial all around the board. Prior to his time at his current position he managed the Aries Fund (1994 or 2007) and the Orion Fund (2002 to 2006), both of which have made substantial contributions to furthering the efforts of biotechnology and life science companies and their initiatives.

Investors can be sure that with Lindsay Rosenwald managing their investments their risks will be minimal. Rosenwald and Weiss specifically hand pick biotech companies that show not only promise of positive investment growth but also of potentially successful drug research and trials. OpusPoint Partners are committed to staying true to their integrity on both the financial and science areas. A motto of prevailing honesty and discretion is what keeps investors with this company.

OpusPoint Partners sets itself apart from the competition by way of Rosenwald and Weiss’ dedication to remain transparent with their investors and being unyielding in their expectations for ethical research and trials of potentially lifesaving medicine. This steadfastness combined with the immense competency both men bring to the company ensures that OpusPoint Partners will experience continued progression and be a part of necessary discoveries in the biotech industry.

In less than two years at OpusPoint Partners, Lindsay Rosenwald has assisted in financing and mentoring more than 20 biotech companies through his robust financing connections in the biotechnology and life science sectors. OpusPoint Partners still has much more to accomplish and it is obvious that this company is in for a steady run of growth in the years to come.

Lindsay Rosenwald activities outside of his career include being a member of the Board of Directors of the Republican Jewish Coalition.

« Older Entries

Optimized by SEO Ultimate